Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1992)
  2. Solid Tumor Oncology Division (1623)
  3. GSK Faculty (765)
  4. Survivorship Research (637)
  5. Population Sciences Research Program (614)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (414)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2106)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (90)
  5. Editorial (83)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1992)
  2. Solid Tumor Oncology Division (1623)
  3. GSK Faculty (765)
  4. Survivorship Research (637)
  5. Population Sciences Research Program (614)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (101)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (846)
  3. JNCI: Journal of the National Cancer Institute (484)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (138)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4648)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase I/II study of davutamig (REGN5093), a METxMET bispecific antibody, in patients with MET-altered, advanced non-small cell lung cancer (aNSCLC): Trial in progress update
    Meeting Abstract

    Ahn, M. J.; Cho, B.; Kim, T. M.; Han, J. Y.; Kim, C.; Shim, B.; Drilon, A.; Blumenschein, G.; Villaruz, L.; Gray, J. E.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with adult-type diffuse glioma with an IDH1/2 mutation (INDIGO): Updated efficacy results
    Meeting Abstract

    Mellinghoff, I. K.; van den Bent, M. J.; Touat, M.; Blumenthal, D. T.; Peters, K. B.; Ellingson, B. M.; Clarke, J. L.; Mendez, J.; Yust-Katz, S.; Mason, W. P.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • Long-term efficacy and safety of larotrectinib in patients with TRK fusion primary central nervous system (CNS) tumors: An updated analysis
    Meeting Abstract

    Perreault, S.; Spano, J. P.; Nilsson, A.; Deyell, R. J.; Doz, F.; Geoerger, B.; Gumus, M.; Lassen, U. N.; Nysom, K.; Valero-Arrese, L.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • Evaluation of paxalisib in GBM AGILE phase 3 registration platform trial for newly diagnosed and recurrent glioblastoma
    Meeting Abstract

    Mellinghoff, I. K.; Cloughesy, T.; Alexander, B.; Berry, D. A.; Buxton, M.; Cavenee, W.; Colman, H.; de Groot, J.; Ellingson, B. M.; Gordon, G. B.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • Outcome of patients with recurrent medulloblastoma and ependymoma treated with pembrolizumab, an immune checkpoint inhibitor: A Pediatric Brain Tumor Consortium study (PBTC045)
    Meeting Abstract

    Hwang, E.; Kilburn, L.; Mitchell, D.; Lin, T.; Poussaint, T. Y.; Robinson, G.; Gajjar, A.; Lenzen, A.; Dorris, K.; Robison, N.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • Safety and preliminary efficacy of AZD1390 + radiation therapy for glioblastoma
    Meeting Abstract

    Wen, P.; Yang, J. T.; Imber, B. S.; Drappatz, J.; Jena, R.; Forst, D.; Zukas, A.; Short, S. C.; Fan, C.; Trigg, W.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • A phase 1, safety lead-in and randomized, open-label, perioperative study of vorasidenib combined with pembrolizumab in recurrent or progressive enhancing IDH1 mutant glioma: Trial in progress
    Meeting Abstract

    Wen, P. T.; de la Fuente, M.; Kumthekar, P.; Peters, K.; Clarke, J.; de Groot, J.; Arrillaga-Romany, I.; Puduvalli, V.; Mellinghoff, I.; Chong, R.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • Alliance A071401: Genomically guided phase II trial of abemaciclib in patients with grade 2/3 meningiomas harboring somatic NF2 or CDK pathway alterations
    Meeting Abstract

    Brastianos, P.; Dooley, K.; Geyer, S.; Gerstner, E.; Kaufmann, T.; Iafrate, A. J.; Martinez-Lage, M.; Milhem, M.; Welch, M.; Kaley, T.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • Update on GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma
    Meeting Abstract

    Lassman, A.; Alexander, B.; Berry, D.; Berry, N.; Buxton, M.; Colman, H.; Gan, H.; de Groot, J.; de la Fuente, M.; Drappatz, J.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • IDH-mutant glioma patients treated with vorasidenib: Ongoing data from the vorasidenib expanded access program
    Meeting Abstract

    Cloughesy, T.; Peters, K.; Colman, H.; Taylor, J.; Mellinghoff, I.; Shih, H.; Chacar, C.; Dewey, J.; Wen, P.
    Neuro-Oncology (2024)

    Fulltext@MSK | Save